Home Investors  >  Financials  >  Debt Securities

Debt Securities

Teva's senior notes and debentures and convertible debentures are issued by various special-purpose finance subsidiaries. All such debt is guaranteed by Teva Pharmaceutical Industries Ltd.

Quarterly Debt Factsheet

Senior Notes and Debentures

Issued
Currency
Annual Interest
(%)
Principal Amount Issued
(U.S. $ in MM)
Current Outstanding
Due
Prospectuses
January 2006 USD 6.150 1,000 779 January 2036
November 2011 USD 3.650 1,750 1,202 November 2021
December 2012 USD 2.950 1,300 851 December 2022
March 2015 Euro 1.250 1,480 1,594 March 2023
March 2015 Euro 1.875 789 857 March 2027
July 2016 USD 2.200 3,000 1,473 July 2021
July 2016 USD 2.800 3,000 2,992 July 2023
July 2016 USD 3.150 3,500 3,486 October 2026
July 2016 USD 4.100 2,000 1,972 October 2046
July 2016 CHF 0.500 357 397 July 2022
July 2016 CHF 1.000 357 397 July 2025
July 2016 Euro 0.375 1,947 - July 2020

July 2016 Euro 1.125 1,669 1,836 October 2024
July 2016 Euro 1.625 834 914 October 2028
March 2018 USD 6.000 1,250 1,245 April 2024
March 2018 USD 6.750 1,250 1,243 March 2028
March 2018 Euro 3.250 867 859 April 2022
March 2018 Euro 4.500 1,115 1,103 March 2025
November 2019 USD 7.125 1,000 993 January 2025
November 2019 Euro 6.0 1,120 1,220 January 2025

Convertible Senior Debentures

Issued Annual interest rate
(%)
Initial Principal amount
(U.S. $ in MM)
Principal amount at 2/1/2021 Year due Conversion price August 2018
(U.S. $)
No of Teva shares issuable upon full conversion at 3/31/2017
(in MM)

January 2006(1) 0.25 $575 $23 2026 $39.7841 See footnote 1

To view the prospectus supplement relating to the January 2006 debentures - click here
For conversion and other notices - click here

(1) These convertible senior debentures due 2026 include a "net share settlement" feature according to which the principal of the debentures will be paid in cash and in the case of conversion, only the residual conversion value above the principal will be paid in Teva shares.

Term Loans and Other Facilities

Source Year
of
Facility
Currency Annual
Interest Rate (%)
(%)
Principal Amount
Issued
(U.S. $ in MM)
Due Additional Information

Revolving Credit Facility A

2019 USD USD Libor +1.75 - N/A $1.15 b facility available for 3 years with two 1 year extensions
$1.065 b extended for additional year

Revolving Credit Facility B

2019 USD USD Libor +1.95 - N/A $1.15 b facility available for 5 years

On April 8th 2019 Teva has entered into a new $2.3 billion revolving credit facility agreement. To view the new agreement – click here